Background
Dr. Sorror is a blood and marrow transplant (BMT) specialist whose work centers on improving care for patients with aggressive blood cancers, particularly those who are older, frail or have other medical conditions. He specializes in both autologous stem cell transplantation, which uses a patient’s own cells, and allogeneic transplantation, which uses cells from a compatible donor.
Much of Dr. Sorror’s career focuses on clinical research designed to help patients and their physicians make better, more personalized treatment decisions. He and his colleagues pioneered the first widely used scoring system to predict the risks of stem cell transplantation for an individual patient. He also integrated geriatric assessments into decision-making for leukemia treatment with chemotherapy or BMT.
Dr. Sorror leads multicenter clinical trials that test supportive and palliative care, exercise programs and targeted management of medical conditions to improve BMT outcomes for vulnerable patients. Through both clinical and population-based studies, he develops and validates tools to predict survival, treatment side effects and quality of life. His work also explores patient experiences, values and treatment preferences to ensure therapies align with what matters most to them. Additionally, he is leading efforts to improve access to BMT and immunotherapy for patients from underrepresented groups or those facing socioeconomic barriers.
Throughout his career, Dr. Sorror has served as principal investigator on grants from the National Cancer Institute, National Heart, Lung and Blood Institute, American Cancer Society and Patient-Centered Outcomes Research Institute. He also holds several leadership positions with national and international organizations, such as the Bone Marrow Transplant Clinical Trials Network.
Area of Clinical Practice
Adult blood and marrow transplantation, cellular immunotherapy, blood cancers
